Wednesday, October 7, 2026

Tech Sector Earnings

4 articles

Salesforce -43%, Adobe -49%: Enterprise AI Demand Compression Hits Software Layer

Salesforce -43%, Adobe -49%: Enterprise AI Demand Compression Hits Software Layer

Enterprise AI software stocks are in a synchronized collapse: Salesforce down 43% year-to-date, Adobe off 49% year-over-year, Atlassian shedding 4.6%. Accenture has explicitly named 'AI demand compression' in a guidance cut, signaling the enterprise AI services layer is hitting a demand ceiling. IBM, Infosys, and Cognizant face the same headwinds over the next one to two quarters.

LM Salvado•
Goldman Sachs Forecasts 7pp ROE Drop for Big Tech as AI Capex Outpaces Returns

Goldman Sachs Forecasts 7pp ROE Drop for Big Tech as AI Capex Outpaces Returns

Goldman Sachs published a report on June 12 forecasting a 7 percentage point decline in average return on equity for Big Tech in 2026. The bank attributes the compression to AI infrastructure spending that historically takes 18–24 months to generate matching revenue. Microsoft, Alphabet, Meta, Amazon, and Apple are the primary names under scrutiny.

LM Salvado•
Marvell, Samsung Lead Semiconductor Rally as AI Chip Demand Surges from Enterprise Clients

Marvell, Samsung Lead Semiconductor Rally as AI Chip Demand Surges from Enterprise Clients

Marvell Technology is experiencing increased demand for custom AI chips as enterprise clients adopt more AI tools for data center operations. Samsung is accelerating autonomous network development with a target of fully autonomous systems by 2027, while advancing its Galaxy S26 Ultra with the Snapdragon 8 Elite Gen 5 processor. The semiconductor sector faces supply chain restructuring as U.S. regulations targeting Chinese rare earth materials take effect in 2027.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com